Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 7/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | BRS3 | P32247 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216313 | 0.89 | FYN (0.56) | FYNKDM1ABRS3KCNH2NPC1 | |
| SCHEMBL32670328 | 0.81 | CYP11B1 (0.47) | FYNBRS3KCNH2NPC1RXFP1 | |
| SCHEMBL507838 | 0.81 | CYP11B1 (0.47) | FYNBRS3KCNH2NPC1RXFP1 | |
| SCHEMBL3823318 | 0.81 | RAB9A (0.53) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL30083483 | 0.81 | LOXL2 (0.54) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL17610081 | 0.81 | CYP11B1 (0.47) | FYNBRS3KCNH2NPC1RXFP1 | |
| SCHEMBL16675751 | 0.80 | FYN (0.52) | FYNGRM5CDK8 | |
| SCHEMBL3511950 | 0.80 | NPC1 (0.51) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL19407055 | 0.79 | SMN1; SMN2 (0.56) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL3822972 | 0.79 | NPC1 (0.46) | FYNBRS3KCNH2NPC1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2012133607-A1 | PYRAZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2012-10-04 | — | — | WO | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | FYN 2929/4885KDM1A 3156/4885BRS3 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.